Tokyo, Sept 7, 2006 (JCN) - Takara Bio Inc., a forerunner in cancer treatment, has offered its RetroNectin for the treatment chronic lymphatic leukemia in phase-I clinical trials currently being conducted at the U.S. Memorial Sloan-Kettering Cancer Center (MSKCC).
